Protect Animal Health Partners with Rejuvenate Bio to Combat Canine Heart Disease

Protect Animal Health, a leading life sciences company in Taiwan, has entered a licensing agreement with Rejuvenate Bio, a biotechnology firm specializing in gene therapies, with the aim to develop PT-401, a gene therapy targeting Myxomatous Mitral Valve Disease (MMVD) in dogs. This partnership grants Protect exclusive rights to distribute and market PT-401 across the Asia-Pacific region. MMVD affects a significant percentage of dogs, particularly small breeds, leading to severe heart conditions as they age. The therapy has already shown efficacy in preclinical trials in the US, demonstrating long-term gene expression and a strong safety profile. Protect plans to initiate trials in Taiwan by the end of 2024. This collaboration between Protect and Rejuvenate Bio combines expertise in gene therapy with regional distribution capabilities, addressing a significant unmet need in veterinary care. Protect Animal Health, under CEO Haolin Sung's leadership, is committed to advancing animal welfare through innovative solutions, while Rejuvenate Bio continues its mission to enhance the lives of pets globally.